Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Kimer Med General Information
Kimer Med has demonstrated in vitro efficacy against 21 different viruses across nine virus families and positive early in vivo data confirming efficacy and low toxicity. The lead candidate targets Dengue fever, with first significant revenue projected for 2028. The company plans to out-license its lead after successful Phase 1 trials[2][1].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Nelson, Nelson Region
New Zealand
New Zealand
Drug Pipeline
VTose
Pre-clinicalKey Partnerships
Battelle Memorial Institute / US Defense Threat Reduction Agency for alphavirus program development contract ($750k USD)[4]
Kimer Med Funding
No funding data available
To view Kimer Med's complete valuation and funding history, request access »